



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 171038**

**TO: Deborah Lambkin**  
**Location: REM/5B09/5C18**  
**Art Unit: 1626**  
**Tuesday, November 22, 2005**

**Case Serial Number: 10/662046**

**From: Paul Schulwitz**  
**Location: Biotech-Chem Library**  
**REM-1A65**  
**Phone: 571-272-2527**

**Paul.schulwitz@uspto.gov**

### **Search Notes**

Examiner Lambkin,

Please review the attached search results.

If you have any questions or if you would like to refine the search query, please feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz  
Technical Information Specialist  
REM-1A65  
571-272-2527



# STIC SEARCH RESULTS FEEDBACK FORM

## Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor  
Remsen Bldg. 01 D86  
571-272-2507

## Voluntary Results Feedback Form

➤ I am an examiner in Workgroup:  Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature  
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Deborah Lambdin Examiner #: 71300 Date: 11/8/05  
 Art Unit: 1626 Phone Number 302-0698 Serial Number: 10662046  
 Mail Box and Bldg/Room Location: 5B09 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.


\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Inhibitors of Tumor XA  
 Inventors (please provide full names): Conroy Louis Bolton et al

Earliest Priority Filing Date: \_\_\_\_\_

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Also can you search any one of the compounds listed in Cl. 22.

Thanks Dan

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: _____	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

# Application

Lambkin 10/662,046

11/22/2005

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:252476 HCAPLUS  
DOCUMENT NUMBER: 140:287179  
ENTRY DATE: Entered STN: 26 Mar 2004  
TITLE: Preparation of [phenylureido(hetero)cyclyl]carboxamide  
s as inhibitors of factor Xa and other serine  
proteases involved in the coagulation cascade  
INVENTOR(S): Bolton, Gary Louis; Filipski, Kevin James; Kohrt,  
Jeffrey Thomas; La, Frances Thu; Leonard, Daniele  
Marie  
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA  
SOURCE: PCT Int. Appl., 111 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
INT. PATENT CLASSIF.:  
MAIN: C07C317-32  
SECONDARY: C07D213-75; C07C311-46; C07D309-14; C07D335-02;  
C07D211-76; C07D207-16; A61K031-17; A61K031-18  
CLASSIFICATION: 25-21 (Benzene, Its Derivatives, and Condensed  
Benzenoid Compounds)  
Section cross-reference(s): 1, 63  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024679	A1	20040325	WO 2003-IB3900	20030902
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497003	AA	20040325	CA 2003-2497003	20030902
EP 1539686	A1	20050615	EP 2003-795154	20030902
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014219	A	20050719	BR 2003-14219	20030902
US 2004167131	A1	20040826	US 2003-662046	20030911 <--
PRIORITY APPLN. INFO.:			US 2002-409891P	P 20020911
			WO 2003-IB3900	W 20030902

## PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004024679	ICM	C07C317-32
	ICS	C07D213-75; C07C311-46; C07D309-14; C07D335-02; C07D211-76; C07D207-16; A61K031-17; A61K031-18
WO 2004024679	ECLA	C07C311/46; C07C317/32; C07D207/16; C07D211/76; C07D213/75D3; C07D309/14; C07D335/02
BR 2003014219	ECLA	C07C311/46; C07C317/32; C07D207/16; C07D211/76; C07D213/75D3; C07D309/14; C07D335/02
US 2004167131	NCL	514/237.500
	ECLA	C07C311/46; C07C317/32; C07D207/16; C07D211/76;

C07D213/75D3; C07D309/14; C07D335/02  
MARPAT 140:287179

&lt;--

OTHER SOURCE(S):  
GRAPHIC IMAGE:

## ABSTRACT:

Title amino acid derivs. I [wherein X1 and X2 = independently H, (ar)alkyl, alkenyl, alkynyl, (hetero)aryl, cycloalkyl(alkyl), (CH<sub>2</sub>)<sub>m</sub>-halo, (CH<sub>2</sub>)<sub>m</sub>-heteroaryl, (CH<sub>2</sub>)<sub>m</sub>SOR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>OCOR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>OSO<sub>2</sub>R<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>OSO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>NR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>OR<sub>3</sub>, CN, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>O(CH<sub>2</sub>)<sub>m</sub>OR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>O(CH<sub>2</sub>)<sub>m</sub>NR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>R<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>COR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CONR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>NR<sub>6</sub>COR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>NR<sub>6</sub>CONR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>R<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>-morpholinyl, (CH<sub>2</sub>)<sub>m</sub>-piperazinyl, etc.; or CX<sub>1</sub>X<sub>2</sub> = (hetero)cyclyl; A = aryl(cycloalkyl), heteroaryl(cycloalkyl), cycloalkyl, or cycloalkenyl; M = (hetero)arylene, (hetero)cycloalkylene, or (hetero)cycloalkenylene; Q = CONR<sub>4</sub>R<sub>5</sub>, (hetero)aryl, (hetero)cycloalkyl, or (hetero)cycloalkenyl; R<sub>1</sub> = H, alkyl, (hetero)aryl, or alkenyl; R<sub>2</sub> = H, (cyclo)alkyl, (hetero)aryl, alkenyl, (hetero)cycloalkylalkyl, (hetero)aralkyl, carboxy, (CH<sub>2</sub>)<sub>m</sub>NR<sub>4</sub>R<sub>5</sub>, (CH<sub>2</sub>)<sub>m</sub>OR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>SR<sub>3</sub>, (CH<sub>2</sub>)<sub>m</sub>CONR<sub>4</sub>R<sub>5</sub>, or (CH<sub>2</sub>)<sub>m</sub>NR<sub>6</sub>COR<sub>3</sub>; R<sub>3</sub> and R<sub>6</sub> = independently H, (ar)alkyl, (hetero)aryl, alkenyl, alkynyl, cycloalkyl(alkyl), or heteroarylalkyl; R<sub>4</sub> and R<sub>5</sub> = independently H, (ar)alkyl, (hetero)aryl, alkenyl, alkynyl, cycloalkyl(alkyl), heteroarylalkyl, acyl, alkoxycarbonyl, alkylthiocarbonyl, or alkylcarbonyl; or NR<sub>4</sub>R<sub>5</sub> = heterocyclyl; m = 0-8; and pharmaceutically acceptable salts thereof] were prepared as serine protease factor Xa inhibitors. For example, 1-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid was condensed with 4-bromoaniline using EEDQ and TEA in CHCl<sub>3</sub> to give the amide (55%). Coupling with 2-(methylthio)benzeneboronic acid in the presence of tetrabutylammonium bromide and Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, Pd(PPh<sub>3</sub>)<sub>4</sub> in toluene provided the biphenyl derivative (57%). Oxidation to the mesyl derivative with m-CPBA in EtOAc (79%), followed by treatment with TFA in DCM and reaction with 4-chlorophenyl isocyanate using TEA in THF gave the desired urea II (82%). The latter suppressed cleavage of a fluorogenic substrate by human factor Xa (3 pM) with a IC<sub>50</sub> value of 38 nM and increased prothrombin clotting time by 2-fold at a concentration of 13.46 μM. Thus, I and pharmaceutically acceptable compns. comprising them are useful as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis (no data).

SUPPL. TERM: phenylureidoheterocyclyl carboxamide prepn serine protease factor Xa inhibitor; cycloalkyl phenyl urea prepn thrombosis treatment

INDEX TERM: Heart, disease  
(angina pectoris; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Thrombosis  
(arterial; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Heart, disease  
(atrial fibrillation; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Drug delivery systems  
(capsules, hard gelatin; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Blood coagulation  
(disorder; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Lung, disease  
(embolism; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Heart, disease  
(failure; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Brain, disease  
Heart, disease  
(infarction; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Drug delivery systems  
(injections, i.v.; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Antianginal agents  
Anticoagulants  
Antidiabetic agents  
Antitumor agents  
Cardiovascular agents  
Diabetes mellitus  
Human  
Neoplasm  
Thrombolytics  
Thrombosis  
(preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Embolism  
(pulmonary; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Artery, disease  
(restenosis; preparation of [phenylureido(hetero)cyclyl]carbox

amides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Drug delivery systems  
(tablets; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: Thrombosis  
(venous; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

INDEX TERM: 675833-57-5P, 1-[3-(4-Chlorophenyl)ureido]cyclopentanecarboxylic acid N-[2'-(methanesulfonyl)biphenyl-4-yl]amide  
675833-63-3P, 1-[3-(4-Chlorophenyl)ureido]cyclopropanecarboxylic acid N-[2'-(methanesulfonyl)biphenyl-4-yl]amide  
675833-67-7P, 1-[3-(4-Chlorophenyl)ureido]cyclopropanecarboxylic acid N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide 675833-70-2P, 1-[3-(5-Chloropyridin-2-yl)ureido]cyclopropanecarboxylic acid N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide 675833-71-3P, 1-[3-(4-Chlorophenyl)ureido]cyclopropanecarboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide  
675833-74-6P, 1-[3-(5-Chloropyridin-2-yl)ureido]cyclopropanecarboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide 675833-75-7P, 2-[3-(4-Chlorophenyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]-2-methylpropionamide  
675833-78-0P, 2-[3-(5-Chloropyridin-2-yl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]-2-methylpropionamide 675833-79-1P, 2-[3-(4-Chlorophenyl)ureido]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-2-methylpropionamide  
675833-82-6P, 1-[3-(4-Chlorophenyl)ureido]cyclohexanecarboxylic acid N-[2'-(methanesulfonyl)biphenyl-4-yl]amide  
675833-86-0P, 1-[3-(4-Chlorophenyl)ureido]cyclopent-3-ene-1-carboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide 675833-89-3P, 2-[3-(4-Chlorophenyl)-1-methylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675833-92-8P, 2-[3-(4-Chlorophenyl)-3-methylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675833-95-1P, 2-[3-(4-Chlorophenyl)-1,3-dimethylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675833-96-2P, 2-[3-(4-Chlorophenyl)ureido]-3-hydroxy-2-hydroxymethyl-N-(2'-sulfamoylbiphenyl-4-yl)propionamide 675834-01-2P  
675834-03-4P, 4-[3-(4-Chlorophenyl)ureido]-3,4,5,6-tetrahydro-2H-thiopyran-4-carboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide  
675834-06-7P, (1S,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide  
675834-10-3P, (1S,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide  
675834-11-4P, (1R,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide  
675834-15-8P, (1R,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide

675834-16-9P, 3-[3-(4-Chlorophenyl)ureido]-3-[[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]carbamoyl]pyrrolidine-1-carboxylic acid benzyl ester  
 675834-22-7P, 2-[3-(4-Chlorophenyl)-1-(cyclopropylmethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
 675834-25-0P, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
 675834-26-1P, 2-[3-(4-Chlorophenyl)-1-isobutylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
 675834-27-2P, 2-[3-(4-Chlorophenyl)-1-(2-dimethylaminoethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
 675834-28-3P, 2-[1-Benzyl-3-(4-chlorophenyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
 675834-29-4P, 2-[3-(4-Chlorophenyl)-1-(4-methoxybenzyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
 675834-30-7P, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]acetamide

ROLE: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(factor Xa inhibitor; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

## INDEX TERM:

145602-88-6P, Methyl 3-amino-1-benzylpyrrolidine-3-carboxylate 209919-51-7P, 4'-Amino-3'-fluorobiphenyl-2-sulfonic acid tert-butylamide 536746-34-6P, (5-Chloropyridin-2-yl)carbamic acid 4-nitrophenyl ester  
 675833-59-7P, [1-(4-Bromophenylcarbamoyl)cyclopentyl]carbamic acid tert-butyl ester 675833-60-0P, [1-[(2'-Methylsulfanylbiphenyl-4-yl)carbamoyl]cyclopentyl]carbamic acid tert-butyl ester 675833-62-2P, [1-[(2'-(Methanesulfonyl)biphenyl-4-yl)carbamoyl]cyclopentyl]carbamic acid tert-butyl ester 675833-64-4P, [1-(4-Bromophenylcarbamoyl)cyclopropyl]carbamic acid tert-butyl ester 675833-65-5P, [1-[(2'-Methylsulfanylbiphenyl-4-yl)carbamoyl]cyclopropyl]carbamic acid tert-butyl ester  
 675833-66-6P, [1-[(2'-(Methanesulfonyl)biphenyl-4-yl)carbamoyl]cyclopropyl]carbamic acid tert-butyl ester  
 675833-68-8P, [1-[(3-Fluoro-2'-methylsulfanylbiphenyl-4-yl)carbamoyl]cyclopropyl]carbamic acid tert-butyl ester  
 675833-69-9P, [1-[(3-Fluoro-2'-(methanesulfonyl)biphenyl-4-yl)carbamoyl]cyclopropyl]carbamic acid tert-butyl ester  
 675833-72-4P, [1-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]cyclopropyl]carbamic acid tert-butyl ester 675833-73-5P, 1-Aminocyclopropanecarboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide 675833-76-8P, [1-[(3-Fluoro-2'-methylsulfanylbiphenyl-4-yl)carbamoyl]-1-methylethyl]carbamic acid tert-butyl ester 675833-77-9P, [1-[(3-Fluoro-2'-(methanesulfonyl)biphenyl-4-yl)carbamoyl]-1-methylethyl]carbamic acid tert-butyl ester  
 675833-80-4P, [1-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]-1-methylethyl]carbamic acid tert-butyl ester 675833-81-5P,



2-Amino-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-2-methylpropionamide 675833-83-7P, [1-(4-Bromophenylcarbonyl)cyclohexyl]carbamic acid tert-butyl ester 675833-84-8P, [1-[(2'-Methylsulfanylbiphenyl-4-yl)carbonyl]cyclohexyl]carbamic acid tert-butyl ester 675833-85-9P, [1-[(2'-(Methanesulfonyl)biphenyl-4-yl)carbonyl]cyclohexyl]carbamic acid tert-butyl ester 675833-87-1P, [1-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbonyl]cyclopent-3-enyl]carbamic acid tert-butyl ester 675833-88-2P, 1-[3-(4-Chlorophenyl)ureido]cyclopent-3-ene-1-carboxylic acid N-(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide 675833-90-6P, [[(3-Fluoro-2'-methylsulfanylbiphenyl-4-yl)carbonyl]methyl](methyl)carbamic acid tert-butyl ester 675833-91-7P, [[[3-Fluoro-2'-(methanesulfonyl)biphenyl-4-yl]carbonyl]methyl](methyl)carbamic acid tert-butyl ester 675833-97-3P, [5-(4-Bromophenylcarbonyl)-2-phenyl-[1,3]dioxan-5-yl]carbamic acid tert-butyl ester 675833-98-4P, [5-[(2'-(tert-Butylsulfamoyl)biphenyl-4-yl)carbonyl]-2-phenyl-[1,3]dioxan-5-yl]carbamic acid tert-butyl ester 675833-99-5P, [1-[(2'-(tert-Butylsulfamoyl)biphenyl-4-yl)carbonyl]-2-hydroxy-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 675834-00-1P, N-[2'-(tert-Butylsulfamoyl)biphenyl-4-yl]-2-[3-(4-chlorophenyl)ureido]-3-hydroxy-2-hydroxymethylpropionamide 675834-02-3P, [4-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbonyl]tetrahydropyran-4-yl]carbamic acid tert-butyl ester 675834-04-5P, [4-(4-Bromo-2-fluorophenylcarbonyl)tetrahydrothiopyran-4-yl]carbamic acid tert-butyl ester 675834-05-6P, [4-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbonyl]tetrahydrothiopyran-4-yl]carbamic acid tert-butyl ester 675834-07-8P, (1S,2S)-1-[(tert-Butoxycarbonyl)carbonyl]-2-(hydroxymethyl)cyclopropanecarboxylic acid 675834-08-9P, (1S,2S)-1-[(tert-Butoxycarbonyl)carbonyl]-2-[(1,1,2,2-tetramethyl-1-silapropoxy)methyl]cyclopropanecarboxylic acid 675834-09-0P, (1S,2S)-1-[(tert-Butoxycarbonyl)carbonyl]-2-[(1,1,2,2-tetramethyl-1-silapropoxy)methyl]-N-[2-fluoro-4-[2-(methylsulfonyl)phenyl]phenyl]cyclopropanecarboxamide 675834-12-5P, (1R,2S)-2-(Acetyloxymethyl)-1-[(tert-butoxycarbonyl)carbonyl]cyclopropanecarboxylic acid 675834-13-6P 675834-14-7P 675834-17-0P, Methyl 3-[(tert-butoxycarbonyl)carbonyl]-1-benzylpyrrolidine-3-carboxylate 675834-18-1P, Methyl 3-[(tert-butoxycarbonyl)carbonyl]-1-(benzyloxycarbonyl)pyrrolidine-3-carboxylate 675834-19-2P, 3-[(tert-Butoxycarbonyl)carbonyl]-1-(benzyloxycarbonyl)pyrrolidine-3-carboxylic acid 675834-20-5P, Phenylmethyl 3-[(tert-butoxycarbonyl)carbonyl]-3-[[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]carbonyl]pyrrolidine-1-carboxylate 675834-21-6P, Phenylmethyl 3-amino-3-[[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]carbonyl]pyrrolidine-1-carboxylate 675834-23-8P, 2-Bromo-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-24-9P, 2-[(Cyclopropylmethyl)amino]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide  
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of [phenylureido(hetero)cyclyl]carb  
oxamides as factor Xa inhibitors for treatment of  
abnormal thrombosis)

INDEX TERM: 9001-26-7, Prothrombin 9002-04-4, Thrombin 9002-05-5,  
Factor Xa

ROLE: BSU (Biological study, unclassified); BIOL (Biological  
study)

(preparation of [phenylureido(hetero)cyclyl]carboxamides as  
factor Xa inhibitors for treatment of abnormal  
thrombosis)

INDEX TERM: 78-81-9, Isobutylamine 104-12-1, 4-Chlorophenyl isocyanate

106-40-1, 4-Bromoaniline 108-00-9, N,N-

Dimethylethylenediamine 109-85-3, 2-Methoxyethylamine

367-24-8, 4-Bromo-2-fluoroaniline 501-53-1, Benzyl

chloroformate 1072-98-6, 2-Amino-5-chloropyridine

2393-23-9, 4-Methoxybenzylamine 2516-47-4,

(Aminomethyl)cyclopropane 7693-46-1, 4-Nitrophenyl

chloroformate 13734-36-6, [(tert-

Butoxycarbonyl)(methyl)amino]acetic acid 18162-48-6,

tert-Butyldimethylsilyl chloride 30280-44-5,

p-Chlorobenzyl isocyanate 30992-29-1, 2-[(tert-

Butoxycarbonyl)amino]-2-methylpropionic acid 35264-09-6,

1-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid

88950-64-5, 1-[(tert-Butoxycarbonyl)amino]cyclopropanecarbox

ylic acid 108329-81-3, 4-[(tert-

Butoxycarbonyl)amino]tetrahydrothiopyran-4-carboxylic acid

115951-16-1, 1-[(tert-Butoxycarbonyl)amino]cyclohexanecarbox

ylic acid 127181-30-0 131304-84-2, (2-Oxo-3-

oxabicyclo[3.1.0]hex-1-yl)carbamic acid tert-butyl ester

150691-04-6, 2-tert-Butylsulfamoylphenylboronic acid

154627-63-1, 5-[(tert-Butoxycarbonyl)amino]-2-phenyl-

[1,3]dioxane-5-carboxylic acid 168210-66-0,

3-(Benzhydrylideneamino)-1-benzylpyrrolidine-3-carboxylic

acid methyl ester 168618-42-6, 2-

(Methylthio)benzeneboronic acid 172843-97-9,

4-[(tert-Butoxycarbonyl)amino]-3,4,5,6-tetrahydro-2H-pyran-4-

carboxylic acid 209732-08-1, (3-Fluoro-2'-

methylsulfanyl)biphenyl-4-yl)amine 209960-89-4,

1-(4-Amino-3-fluorophenyl)-2-(methylsulfonyl)benzene

213316-20-2, 1-[(tert-Butoxycarbonyl)amino]cyclopent-3-ene-1-

carboxylic acid 444002-54-4, 1-(4-Amino-3-

fluorophenyl)piperidin-2-one 675833-93-9,

2-Amino-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-

yl]acetamide 675833-94-0, [(4-

Chlorophenyl)(methyl)amino]chloroformate

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(preparation of [phenylureido(hetero)cyclyl]carboxamides as  
factor Xa inhibitors for treatment of abnormal  
thrombosis)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD.

REFERENCE(S): (1) Merck Patent GmbH; WO 0248099 A 2002 HCAPLUS  
(2) Warner-Lambert Co; WO 9807718 A 1998 HCAPLUS


IT 675833-57-5P, 1-[3-(4-Chlorophenyl)ureido]cyclopentanecarboxylic  
acid N-[2'-(methanesulfonyl)biphenyl-4-yl]amide 675833-63-3P,  
1-[3-(4-Chlorophenyl)ureido]cyclopropanecarboxylic acid  
N-[2'-(methanesulfonyl)biphenyl-4-yl]amide 675833-67-7P,  
1-[3-(4-Chlorophenyl)ureido]cyclopropanecarboxylic acid

N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide **675833-70-2P**, 1-[3-(5-Chloropyridin-2-yl)ureido]cyclopropanecarboxylic acid  
N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide **675833-71-3P**, 1-[3-(4-Chlorophenyl)ureido]cyclopropanecarboxylic acid  
N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide **675833-74-6P**, 1-[3-(5-Chloropyridin-2-yl)ureido]cyclopropanecarboxylic acid  
N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide **675833-75-7P**, 2-[3-(4-Chlorophenyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]-2-methylpropionamide **675833-78-0P**, 2-[3-(5-Chloropyridin-2-yl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]-2-methylpropionamide **675833-79-1P**, 2-[3-(4-Chlorophenyl)ureido]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-2-methylpropionamide **675833-82-6P**, 1-[3-(4-Chlorophenyl)ureido]cyclohexanecarboxylic acid N-[2'-(methanesulfonyl)biphenyl-4-yl]amide **675833-86-0P**, 1-[3-(4-Chlorophenyl)ureido]cyclopent-3-ene-1-carboxylic acid  
N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide **675833-89-3P**, 2-[3-(4-Chlorophenyl)-1-methylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675833-92-8P**, 2-[3-(4-Chlorophenyl)-3-methylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675833-95-1P**, 2-[3-(4-Chlorophenyl)-1,3-dimethylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675833-96-2P**, 2-[3-(4-Chlorophenyl)ureido]-3-hydroxy-2-hydroxymethyl-N-(2'-sulfamoylbiphenyl-4-yl)propionamide **675834-01-2P**  
**675834-03-4P**, 4-[3-(4-Chlorophenyl)ureido]-3,4,5,6-tetrahydro-2H-thiopyran-4-carboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide **675834-06-7P**, (1S,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide **675834-10-3P**, (1S,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide **675834-11-4P**, (1R,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]amide **675834-15-8P**, (1R,2S)-1-[3-(4-Chlorophenyl)ureido]-2-hydroxymethylcyclopropanecarboxylic acid N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide **675834-16-9P**, 3-[3-(4-Chlorophenyl)ureido]-3-[[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]carbamoyl]pyrrolidine-1-carboxylic acid benzyl ester **675834-22-7P**, 2-[3-(4-Chlorophenyl)-1-(cyclopropylmethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675834-25-0P**, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675834-26-1P**, 2-[3-(4-Chlorophenyl)-1-isobutylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675834-27-2P**, 2-[3-(4-Chlorophenyl)-1-(2-dimethylaminoethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675834-28-3P**, 2-[1-Benzyl-3-(4-chlorophenyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675834-29-4P**, 2-[3-(4-Chlorophenyl)-1-(4-methoxybenzyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide **675834-30-7P**, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]acetamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(factor Xa inhibitor; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)


RN 675833-57-5 HCAPLUS

CN Cyclopentanecarboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-63-3 HCAPLUS

CN Cyclopropanecarboxamide, 1-[[[4-chlorophenyl]amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-67-7 HCAPLUS

CN Cyclopropanecarboxamide, 1-[[[4-chlorophenyl]amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-70-2 HCAPLUS

CN Cyclopropanecarboxamide, 1-[[[(5-chloro-2-pyridinyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-71-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-[[[(4-chlorophenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 675833-74-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-[[[(5-chloro-2-pyridinyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 675833-75-7 HCAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675833-78-0 HCAPLUS

CN Propanamide, 2-[[[(5-chloro-2-pyridinyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675833-79-1 HCAPLUS

CN Propanamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 675833-82-6 HCAPLUS

CN Cyclohexanecarboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-86-0 HCAPLUS

CN 3-Cyclopentene-1-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-[[[(4-chlorophenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 675833-89-3 HCAPLUS


CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]methylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 675833-92-8 HCAPLUS




CN Acetamide, 2-[[[(4-chlorophenyl)methylamino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-95-1 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)methylamino]carbonyl]methylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675833-96-2 HCAPLUS

CN Propanamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-hydroxy-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 675834-01-2 HCAPLUS

CN 2H-Pyran-4-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-4-[[[(4-chlorophenyl)amino]carbonyl]amino]tetrahydro- (9CI) (CA INDEX NAME)



RN 675834-03-4 HCAPLUS


CN 2H-Thiopyran-4-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-4-[[[(4-chlorophenyl)amino]carbonyl]amino]tetrahydro- (9CI) (CA INDEX NAME)



RN 675834-06-7 HCAPLUS

CN Cyclopropanecarboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-(hydroxymethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675834-10-3 HCAPLUS

CN Cyclopropanecarboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-2-(hydroxymethyl)-, (1S,2S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 675834-11-4 HCAPLUS

CN Cyclopropanecarboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-(hydroxymethyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 675834-15-8 HCAPLUS


CN Cyclopropanecarboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-2-(hydroxymethyl)-, (1R,2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 675834-16-9 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-[[[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 675834-22-7 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl] (cyclopropylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675834-25-0 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl] (2-methoxyethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)





RN 675834-26-1 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methylpropyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675834-27-2 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][2-(dimethylamino)ethyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675834-28-3 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](phenylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 675834-29-4 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(4-methoxyphenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 675834-30-7 HCAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[2-fluoro-4-(2-oxo-1-piperidiny)phenyl]- (9CI) (CA INDEX NAME)




IT 536746-34-6P, (5-Chloropyridin-2-yl)carbamic acid 4-nitrophenyl ester 675833-72-4P, [1-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]cyclopropyl]carbamic acid tert-butyl ester 675833-73-5P, 1-Aminocyclopropanecarboxylic acid N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide 675833-80-4P, [1-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]-1-methylethyl]carbamic acid tert-butyl ester 675833-81-5P, 2-Amino-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-2-methylpropionamide 675833-87-1P, [1-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]cyclopent-3-enyl]carbamic acid tert-butyl ester 675833-88-2P, 1-[3-(4-Chlorophenyl)ureido]cyclopent-3-ene-1-carboxylic acid N-(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide 675833-98-4P, [5-[[2'-(tert-Butylsulfamoyl)biphenyl-4-yl]carbamoyl]-2-phenyl-[1,3]dioxan-5-yl]carbamic acid tert-butyl ester 675833-99-5P, [1-[[2'-(tert-Butylsulfamoyl)biphenyl-4-yl]carbamoyl]-2-hydroxy-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 675834-00-1P, N-[2'-(tert-Butylsulfamoyl)biphenyl-4-yl]-2-[3-(4-chlorophenyl)ureido]-3-hydroxy-2-hydroxymethylpropionamide 675834-02-3P, [4-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]tetrahydropyran-4-yl]carbamic acid tert-butyl ester 675834-05-6P, [4-[(2'-tert-Butylsulfamoyl-3-fluorobiphenyl-4-yl)carbamoyl]tetrahydrothiopyran-4-yl]carbamic acid tert-butyl ester 675834-14-7P 675834-21-6P, Phenylmethyl 3-amino-3-[[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]carbamoyl]pyrrolidine-1-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)


RN 536746-34-6 HCAPLUS

CN Carbamic acid, (5-chloro-2-pyridinyl)-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 675833-72-4 HCAPLUS

CN Carbamic acid, [1-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 675833-73-5 HCAPLUS

CN Cyclopropanecarboxamide, 1-amino-N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 675833-80-4 HCAPLUS

CN Carbamic acid, [2-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 675833-81-5 HCAPLUS




CN(C)C(=O)Nc1ccc(cc1F)-c2ccccc2S(=O)(=O)N


CN Carbamic acid, [1-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-cyclopenten-1-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



3-Cyclopentene-1-carboxamide, 1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-  
[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-  
(9CI) (CA INDEX NAME)




CN Carbamic acid, [5-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]amino]carbonyl]-2-phenyl-1,3-dioxan-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 675833-99-5 HCAPLUS

CN Carbamic acid, [2-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]amino]-1,1-bis(hydroxymethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 675834-00-1 HCAPLUS

CN Propanamide, 2-[[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-hydroxy-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 675834-02-3 HCAPLUS

CN Carbamic acid, [4-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]tetrahydro-2H-pyran-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 675834-05-6 HCAPLUS


CN Carbamic acid, [4-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]tetrahydro-2H-thiopyran-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 675834-14-7 HCAPLUS

CN Cyclopropanecarboxamide, 2-[(acetyloxy)methyl]-1-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (1S,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675834-21-6 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-amino-3-[[[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

